Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries

OBJECTIVES: The positioning of secukinumab in the treatment of axial SpA (axSpA) and PsA is debated, partly due to a limited understanding of the comparative safety of the available treatments. We aimed to assess the risk of the key safety outcome infections during treatment with secukinumab and TNF...

Descripción completa

Detalles Bibliográficos
Autores principales: Glintborg, Bente, Di Giuseppe, Daniela, Wallman, Johan K, Provan, Sella A, Nordström, Dan, Hokkanen, Anna-Mari, Österlund, Jenny, Kristianslund, Eirik, Kvien, Tore K, Gudbjornsson, Bjorn , Hetland, Merete Lund, Michelsen, Brigitte, Jacobsson, Lennart, Askling, Johan , Lindström, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891432/
https://www.ncbi.nlm.nih.gov/pubmed/35723604
http://dx.doi.org/10.1093/rheumatology/keac358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891432/
https://www.ncbi.nlm.nih.gov/pubmed/35723604
http://dx.doi.org/10.1093/rheumatology/keac358

Ejemplares similares